Valneva says EU regulator accepts its chikungunya vaccine application

Nov 27 (Reuters) – French drugmaker Valneva said on Monday that the application for its vaccine candidate against mosquito-borne viral disease chikungunya was accepted by the European Medicines Agency (EMA) which would now examine the drug in a fast-track procedure.

The EMA “has determined that all essential regulatory elements required for scientific assessment were included in the application,” Valneva said in a statement.

Accelerated assessment reduces the timeframe the EMA review to 150 days from 210 days, Valneva said.

Discover more from The Dispatch

Subscribe now to keep reading and get access to the full archive.

Continue reading

Verified by MonsterInsights